Facebook, Inc. (NASDAQ:FB): Since shares with the company’s first public quarter are out of the way, and forward expectations are likely to be reset, Piper Jaffray believes that now is the time to own stock in Facebook, Inc. There is an Overweight rating on the name and the firm has a $41 price target.
Cerner Corp. (NASDAQ:CERN): Following the company’s second quarter results, Piper Jaffray views the pullback in shares of Cerner Corp., as a buying opportunity. Piper pointed out that management expects the second half of the year to be strong. There is an Overweight rating on the stock, with an $84 price target.
Starbucks Corp. (NASDAQ:SBUX): Following the company’s weaker than expected second quarter results, and in spite of lowering their price target for shares from $62 to $55, Deutsche Bank continues to believe that Starbucks Corp.’s fiscal year 2013 earnings guidance is achievable. The firm maintains a Buy rating on their stock.
Boston Scientific Corporation (NYSE:BSX): Deutsche Bank has added Boston Scientific to the short-term buy list.
Amarin Corporation PLC (NASDAQ:AMRN): Leerink raised their price target for Amarin Corporation PLC, to reflect the Federal Drug Administration’s approval of Vascepa. The firm says that the label looks mostly as expected, and added that it is difficult to tell whether or not the FDA will grant them exclusive rights for their new chemical entity. Leerink believes that Amarin is in a solid position, ahead of a potential company sale, temporary commercial partnership, or in house launch in early 2013. There is an Outperform rating on the name.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.